Azficel-T
| Clinical data | |
|---|---|
| Trade names | Laviv |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Intradermal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
Azficel-T, sold under the brand name Laviv, is a cell therapy product used to treat moderate to severe nasolabial fold wrinkles (the lines running from the sides of the nose to the corners of the mouth) in adults.[1]
The treatment is autologous, meaning it uses the patient’s own cells. Specifically, fibroblasts—cells involved in skin structure and repair—are extracted from a small skin sample, cultured in a laboratory to increase their number, and then re-injected into the patient’s skin to improve appearance.[2]
Azficel-T was approved for medical use in the United States in June 2011.[2]
References
- ^ a b "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Archived from the original on 16 December 2019. Retrieved 1 April 2020.
- ^ a b c "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.
Further reading
- Smith SR, Munavalli G, Weiss R, Maslowski JM, Hennegan KP, Novak JM (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385. S2CID 24901992.
{{cite journal}}: CS1 maint: overridden setting (link)
External links
- "Laviv (azficel-T)". Medscape. 28 September 2019.
- Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov